SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.3
USERS' SCORE
Good
Based on 13 Reviews
8.8
Supplement Facts
Serving Size: 2 Veg Capsules
Amount Per Serving
%DV
Glucosamine Sulfate(from 1,500 mg Glucosamine Potassium Sulfate Complex)
1.1 g (1,100 mg)
†
MSM (Methylsulfonylmethane)
500 mg
†
Chondroitin Sodium Sulfate(from Bovine Cartilage)
50 mg
†
Top Medical Research Studies
9.5
N-Acetyl Glucosamine reduces arthritis
Collagen-induced arthritis: severity and immune response attenuation using multivalent N-acetyl glucosamine.
Study closely examines arthritis treatment
We aimed to understand how N-acetyl glucosamine (GlcNAc), a compound known for its anti-inflammatory properties, affects the development and severity of collagen-induced arthritis (CIA). Our investigation involved applying a special multivalent GlcNAc-terminated glycoconjugate and assessing its influence through various methodologies.
The results were promising. We observed that GlcNAc treatment significantly reduced inflammation at the site of arthritis, notably decreasing the presence of immune cells that contribute to the disease. Furthermore, it appeared to hinder the activation of other immune cells, which are often involved in the production of harmful pro-inflammatory molecules.
Additionally, GlcNAc treatment not only delayed the onset of arthritis symptoms but also eased the severity of these symptoms in many cases. We found that about 18% to 31% of participants treated with GlcNAc completely avoided any arthritis symptoms. Overall, our findings support a new approach to managing arthritis by focusing on the glycobiological aspects of treatment, presenting GlcNAc as a potential therapeutic option for those suffering from this debilitating condition.
The results were promising. We observed that GlcNAc treatment significantly reduced inflammation at the site of arthritis, notably decreasing the presence of immune cells that contribute to the disease. Furthermore, it appeared to hinder the activation of other immune cells, which are often involved in the production of harmful pro-inflammatory molecules.
Additionally, GlcNAc treatment not only delayed the onset of arthritis symptoms but also eased the severity of these symptoms in many cases. We found that about 18% to 31% of participants treated with GlcNAc completely avoided any arthritis symptoms. Overall, our findings support a new approach to managing arthritis by focusing on the glycobiological aspects of treatment, presenting GlcNAc as a potential therapeutic option for those suffering from this debilitating condition.
Read More
9
Potential OA treatment advancements
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
Directly addresses N-acetylglucosamine effects
We explored the potential of N-acetyl-(D)-glucosamine, a compound often used as a dietary supplement for osteoarthritis (OA), to provide effective relief from this chronic joint condition. Our research focused on a series of newly developed prodrugs, specifically targeting ways to enhance the compound's absorption and effectiveness within the body.
We found that some modified versions of N-acetyl-(D)-glucosamine, known as O-3 and O-4 phosphate prodrugs, demonstrated significant chondroprotective effects in vitro. In simple terms, this means they helped protect and support cartilage health, which is vital for those suffering from OA. Notably, the prodrugs that included a specific amino acid called (L)-proline were particularly effective, even outperforming earlier versions.
Overall, our findings suggest that these novel compounds hold promise as new leads in the search for more effective treatments for osteoarthritis. They signify a positive step toward improving the management of this painful and degenerative joint disease.
We found that some modified versions of N-acetyl-(D)-glucosamine, known as O-3 and O-4 phosphate prodrugs, demonstrated significant chondroprotective effects in vitro. In simple terms, this means they helped protect and support cartilage health, which is vital for those suffering from OA. Notably, the prodrugs that included a specific amino acid called (L)-proline were particularly effective, even outperforming earlier versions.
Overall, our findings suggest that these novel compounds hold promise as new leads in the search for more effective treatments for osteoarthritis. They signify a positive step toward improving the management of this painful and degenerative joint disease.
Read More
8
N-acetylglucosamine derivatives show promise
Novel biologically active series of N-acetylglucosamine derivatives for the suppressive activities on GAG release.
Highly relevant to osteoarthritis treatment
We focused our research on the potential of N-acetylglucosamine, a modified form of glucosamine, to impact osteoarthritis, a common degenerative joint disease. Our investigations revealed that N-acetylglucosamine could enhance the oral bioavailability of glucosamine and is reported to have better in vitro chondroprotective effects compared to its parent compound.
To delve deeper into this, we examined N-acetylglucosamine derivatives modified specifically at the N position, using different chemical groups such as benzenesulfonyl and isoxazole. Among the many compounds we tested, we found that the derivatives with 3-(2-chlorobenzene)-5-methyl-isoxazole formyl chloride and p-methoxybenzenesulfonyl chloride were particularly effective at promoting chondrocyte health in our laboratory studies.
Our findings suggest that these newly developed compounds may hold promise as future treatments for osteoarthritis by enhancing joint health and potentially improving the quality of life for those affected by this condition.
To delve deeper into this, we examined N-acetylglucosamine derivatives modified specifically at the N position, using different chemical groups such as benzenesulfonyl and isoxazole. Among the many compounds we tested, we found that the derivatives with 3-(2-chlorobenzene)-5-methyl-isoxazole formyl chloride and p-methoxybenzenesulfonyl chloride were particularly effective at promoting chondrocyte health in our laboratory studies.
Our findings suggest that these newly developed compounds may hold promise as future treatments for osteoarthritis by enhancing joint health and potentially improving the quality of life for those affected by this condition.
Read More
Most Useful Reviews
9.5
Essential supplement
Can't be without! I have taken Now Glucosamine and MSM for years for arthritis in my hands. I tried several brands initially, but there's a significant difference between Now and the others. I’ve been pain-free with no flexibility issues in my hands and ensure I never run out of this supplement. The Amazon price is competitive.
Read More
9.5
Effective for arthritis
Five Stars. This product really helps my arthritis.
Read More
9.5
Symptoms improved noted
Glucosamine effectively improves arthritis symptoms.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.3
- All Researches
9.5
N-Acetyl Glucosamine reduces arthritis
Collagen-induced arthritis: severity and immune response attenuation using multivalent N-acetyl glucosamine.
Study closely examines arthritis treatment
We aimed to understand how N-acetyl glucosamine (GlcNAc), a compound known for its anti-inflammatory properties, affects the development and severity of collagen-induced arthritis (CIA). Our investigation involved applying a special multivalent GlcNAc-terminated glycoconjugate and assessing its influence through various methodologies.
The results were promising. We observed that GlcNAc treatment significantly reduced inflammation at the site of arthritis, notably decreasing the presence of immune cells that contribute to the disease. Furthermore, it appeared to hinder the activation of other immune cells, which are often involved in the production of harmful pro-inflammatory molecules.
Additionally, GlcNAc treatment not only delayed the onset of arthritis symptoms but also eased the severity of these symptoms in many cases. We found that about 18% to 31% of participants treated with GlcNAc completely avoided any arthritis symptoms. Overall, our findings support a new approach to managing arthritis by focusing on the glycobiological aspects of treatment, presenting GlcNAc as a potential therapeutic option for those suffering from this debilitating condition.
The results were promising. We observed that GlcNAc treatment significantly reduced inflammation at the site of arthritis, notably decreasing the presence of immune cells that contribute to the disease. Furthermore, it appeared to hinder the activation of other immune cells, which are often involved in the production of harmful pro-inflammatory molecules.
Additionally, GlcNAc treatment not only delayed the onset of arthritis symptoms but also eased the severity of these symptoms in many cases. We found that about 18% to 31% of participants treated with GlcNAc completely avoided any arthritis symptoms. Overall, our findings support a new approach to managing arthritis by focusing on the glycobiological aspects of treatment, presenting GlcNAc as a potential therapeutic option for those suffering from this debilitating condition.
Read More
9
N-acetylglucosamine shows promise
Partially acetylated chitooligosaccharides bind to YKL-40 and stimulate growth of human osteoarthritic chondrocytes.
Highly relevant findings
We investigated how partially acetylated chitooligosaccharides, specifically the oligomers of N-acetylglucosamine, might influence the growth of chondrocytes—the cells crucial for cartilage health—in people with osteoarthritis. The study focused on the binding of these sugars to YKL-40, a protein that is often associated with inflammation in joints.
Through careful processing of chitin, we derived two forms of chitooligosaccharides: Oligomin™ and T-ChOS™. Our results unveiled that larger versions of these oligosaccharides showed a strong attraction to YKL-40. More significantly, when we exposed osteoarthritic chondrocytes to these compounds, we noted a noteworthy increase in cell growth—up to three times more under certain conditions.
Interestingly, Oligomin™ required a higher concentration compared to T-ChOS™, which demonstrated that smaller oligosaccharides could be effective at lower doses. However, more isn't always better; excessively high concentrations led to reduced benefits. When we introduced chitotriose, a smaller oligosaccharide, it hampered the positive effects seen with the larger forms, suggesting a complex interplay in oligosaccharide behavior in relation to cellular responses.
Overall, these findings indicate a promising new direction in treating joint inflammation and give us hope for developing new therapies aimed at alleviating the discomfort of arthritis.
Through careful processing of chitin, we derived two forms of chitooligosaccharides: Oligomin™ and T-ChOS™. Our results unveiled that larger versions of these oligosaccharides showed a strong attraction to YKL-40. More significantly, when we exposed osteoarthritic chondrocytes to these compounds, we noted a noteworthy increase in cell growth—up to three times more under certain conditions.
Interestingly, Oligomin™ required a higher concentration compared to T-ChOS™, which demonstrated that smaller oligosaccharides could be effective at lower doses. However, more isn't always better; excessively high concentrations led to reduced benefits. When we introduced chitotriose, a smaller oligosaccharide, it hampered the positive effects seen with the larger forms, suggesting a complex interplay in oligosaccharide behavior in relation to cellular responses.
Overall, these findings indicate a promising new direction in treating joint inflammation and give us hope for developing new therapies aimed at alleviating the discomfort of arthritis.
Read More
9
Potential OA treatment advancements
Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.
Directly addresses N-acetylglucosamine effects
We explored the potential of N-acetyl-(D)-glucosamine, a compound often used as a dietary supplement for osteoarthritis (OA), to provide effective relief from this chronic joint condition. Our research focused on a series of newly developed prodrugs, specifically targeting ways to enhance the compound's absorption and effectiveness within the body.
We found that some modified versions of N-acetyl-(D)-glucosamine, known as O-3 and O-4 phosphate prodrugs, demonstrated significant chondroprotective effects in vitro. In simple terms, this means they helped protect and support cartilage health, which is vital for those suffering from OA. Notably, the prodrugs that included a specific amino acid called (L)-proline were particularly effective, even outperforming earlier versions.
Overall, our findings suggest that these novel compounds hold promise as new leads in the search for more effective treatments for osteoarthritis. They signify a positive step toward improving the management of this painful and degenerative joint disease.
We found that some modified versions of N-acetyl-(D)-glucosamine, known as O-3 and O-4 phosphate prodrugs, demonstrated significant chondroprotective effects in vitro. In simple terms, this means they helped protect and support cartilage health, which is vital for those suffering from OA. Notably, the prodrugs that included a specific amino acid called (L)-proline were particularly effective, even outperforming earlier versions.
Overall, our findings suggest that these novel compounds hold promise as new leads in the search for more effective treatments for osteoarthritis. They signify a positive step toward improving the management of this painful and degenerative joint disease.
Read More
9
MSM and mobilee support cartilage health
Methylsulfonylmethane and mobilee prevent negative effect of IL-1β in human chondrocyte cultures via NF-κB signaling pathway.
Relevant but challenging to isolate effects
We investigated how methylsulfonylmethane (MSM) and a herbal extract called mobilee influence arthritis in human chondrocytes, the cells found in cartilage. By exposing these cells to interleukin (IL)-1β—a protein that can cause joint inflammation—we aimed to understand if these treatments could mitigate the damage commonly associated with osteoarthritis (OA).
We took chondrocytes from the femoral heads of patients undergoing hip replacement surgery and treated them with varying amounts of MSM and mobilee in the presence of IL-1β. Our tests measured cell survival and apoptosis—basically whether the cells lived or died—and assessed the levels of key proteins linked to cartilage breakdown and health.
Our results were encouraging. Both MSM and mobilee appeared to significantly reverse the negative effects brought on by IL-1β. Additionally, they managed to combat the activation of NF-κB, a pathway often implicated in inflammation and cell death. By reducing the levels of harmful enzymes and increasing beneficial proteins, these treatments seem to offer a potential new approach to improving joint health in arthritis patients.
In conclusion, this study suggests that MSM and mobilee could play a beneficial role in protecting cartilage cells from the inflammatory damage caused by IL-1β, providing a strong rationale for their consideration in arthritis treatment.
We took chondrocytes from the femoral heads of patients undergoing hip replacement surgery and treated them with varying amounts of MSM and mobilee in the presence of IL-1β. Our tests measured cell survival and apoptosis—basically whether the cells lived or died—and assessed the levels of key proteins linked to cartilage breakdown and health.
Our results were encouraging. Both MSM and mobilee appeared to significantly reverse the negative effects brought on by IL-1β. Additionally, they managed to combat the activation of NF-κB, a pathway often implicated in inflammation and cell death. By reducing the levels of harmful enzymes and increasing beneficial proteins, these treatments seem to offer a potential new approach to improving joint health in arthritis patients.
In conclusion, this study suggests that MSM and mobilee could play a beneficial role in protecting cartilage cells from the inflammatory damage caused by IL-1β, providing a strong rationale for their consideration in arthritis treatment.
Read More
9
MSM improves knee OA treatment
Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial.
Evaluates MSM's combined benefits
We conducted a thoughtful investigation into how Methylsulfonylmethane (MSM) impacts the treatment of knee osteoarthritis (OA) when paired with glucosamine and chondroitin sulfate. In our study, 147 patients diagnosed with Kellgren-Lawrence grade I-II knee OA were randomly divided into three groups. One group received a combination of glucosamine and chondroitin sulfate, the second group received the same combination with MSM, and the third group was given a placebo.
The patients took their assigned capsules daily for three months, and we measured their pain and mobility before treatment and then at 4, 8, and 12 weeks after starting the regimen. The results revealed that the combination of glucosamine, chondroitin sulfate, and MSM offered noticeable clinical benefits for patients with knee OA. However, those taking only glucosamine and chondroitin sulfate experienced no significant improvement compared to the placebo group.
Our findings highlight the potential advantage of supplementing glucosamine and chondroitin with MSM for managing knee osteoarthritis. Nonetheless, the lack of improvement with glucosamine and chondroitin alone calls into question their effectiveness independently of MSM.
The patients took their assigned capsules daily for three months, and we measured their pain and mobility before treatment and then at 4, 8, and 12 weeks after starting the regimen. The results revealed that the combination of glucosamine, chondroitin sulfate, and MSM offered noticeable clinical benefits for patients with knee OA. However, those taking only glucosamine and chondroitin sulfate experienced no significant improvement compared to the placebo group.
Our findings highlight the potential advantage of supplementing glucosamine and chondroitin with MSM for managing knee osteoarthritis. Nonetheless, the lack of improvement with glucosamine and chondroitin alone calls into question their effectiveness independently of MSM.
Read More
User Reviews
USERS' SCORE
Good
Based on 13 Reviews
8.8
- All Reviews
- Positive Reviews
- Negative Reviews
9.5
Essential supplement
Can't be without! I have taken Now Glucosamine and MSM for years for arthritis in my hands. I tried several brands initially, but there's a significant difference between Now and the others. I’ve been pain-free with no flexibility issues in my hands and ensure I never run out of this supplement. The Amazon price is competitive.
Read More
9.5
Effective for arthritis
Five Stars. This product really helps my arthritis.
9.5
Symptoms improved noted
Glucosamine effectively improves arthritis symptoms.
9.5
Joint health protected
Very good! This product is excellent for maintaining joint health. My arthritis problems have improved substantially, and the packaging is also commendable, being quite large.
9.5
Absorption noted positively
My mother remarked that her arthritis has significantly improved, and she is pleased with the product's absorption after continuous use.
Frequently Asked Questions
No FAQs are available for this product and symptom.
